Work

POSTER: MPN-541 Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera With the Hepcidin Mimetic, Rusfertide: Blinded Randomized Withdrawal Results of the Phase 2 Revive Study

Year: 2023

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(23)00662-6

Authors: Naveen Pemmaraju, Marina Kremyanskaya, Andrew Kuykendall, Ellen Ritchie, Jason Gotlib, Aaron Gerds, Jeanne Palmer, Kristen Pettit, Uttam Nath, Abdulraheem Yacoub, Arturo Molina, Nishit Modi, Frank Valone, Sarita Khanna, Suneel Gupta, Srdan Verstovsek, Yelena Ginzburg, Ronald Hoffman

Institutions: The University of Texas MD Anderson Cancer Center, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, Guy's and St Thomas' NHS Foundation Trust, Moffitt Cancer Center, Cornell University, Weill Cornell Medicine, Stanford Cancer Institute, Stanford University, Cleveland Clinic, Mayo Clinic Hospital, University of Michigan, All India Institute of Medical Sciences Rishikesh, University of Kansas Medical Center, Protagonist Therapeutics (United States), Humboldt-Universität zu Berlin, Fraunhofer Institute for Translational Medicine and Pharmacology, Charité – Universitätsmedizin Berlin

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4386270852

FWCI:

Cites:

Cited by:

Related to: 10